Last week, when Mylan CEO Heather Bresch told a congressional panel that her company only makes $50 profit per EpiPen — the emergency allergy treatment that has risen in price by 600% in recent years — lawmakers found that hard to believe. And now that Mylan has revised that profit figure to $80 per EpiPen, the company’s critics are only getting louder. [More]
elijah cummings
Mylan’s Capitol Hill Critics Still Don’t Believe Company Only Makes $80 Profit Per EpiPen
By 9.27.16
Senators Introduce Bill Mandating Formation Of For-Profit College Oversight Committee
By 2.5.15
Back in October, the Department of Education finalized a new rule: career colleges — those schools that offer specialized training programs for certain occpuations — would have to do a better job actually preparing students for gainful emplotment, or they’d lose access to federal student aid. As part of those standards, the DoE rule included the creation of an oversight group. Today, two senators introduced legislation to ensure the task force is providing useful information to policymakers, parents and students.
Members Of Congress Implore Mattel To "Do The Right Thing," Recall Lead-Tainted Toy Blood-Pressure Cuff
By 2.2.08
56 Members of Congress want to know why Mattel CEO Robert Eckert refuses to issue a nationwide recall for a toy blood-pressure cuff that is contaminated with lead. The affected blood-pressure cuff, sold as part of the Fisher-Price Medical Kit, was recalled exclusively in Illinois after Mattel received a complaint from State Attorney General Lisa Madigan. Legislators want Eckert to stand by a pledge made to reassure a jittery public before the holiday buying season that Mattel would ‘earn back our trust with deeds, not just with words.’
